Formation Bio, Inc.

Formation Bio, Inc. is a US-based company focused on developing innovative therapies through its advanced AI-driven drug development platform, streamlining the process of acquiring and optimizing clinical-stage assets. Formation Bio, Inc. specializes in drug development, founded in 2016 and headquartered in New York, US.

The company has raised a total of USD 372. 25 mn across funding rounds, with its most recent being a Series D round on May 21, 2024, led by Andreessen Horowitz. Co-founded by Benjamine Liu, who has a history of entrepreneurial ventures, Formation Bio has successfully executed four deals to date and has not undergone any significant strategy pivots since its inception. Formation Bio specializes in advancing drug development through its proprietary tech-driven, AI-native platform, which accelerates the process for acquiring and developing clinical-stage assets.

The core offerings primarily focus on optimizing drug selection and development, addressing the urgent need for innovative therapies across various therapeutic areas. By leveraging advanced technologies and a multidisciplinary team with extensive expertise, Formation Bio aims to bridge the gap between the rapid pace of scientific discovery and the efficiency of bringing new treatments to market. The company serves a diverse client base that includes pharmaceutical companies, universities, and biotech firms, facilitating partnerships to expedite access to potential treatments. Formation Bio's products and services are primarily available in North America and Europe, targeting markets where unmet patient needs are prevalent and aligning with strategic collaborations to enhance drug accessibility.

Formation Bio generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research institutions. The company’s business model typically involves licensing agreements and joint ventures that allow clients to leverage Formation Bio's advanced drug development technologies. Revenue is structured around milestones in drug development, where payments are made as specific project phases are completed, ensuring alignment of interests between Formation Bio and its partners. Flagship services include their proprietary platform capabilities, which are essential for expediting the drug development lifecycle, thereby enhancing the overall value proposition for their clients.

In May 2024, Formation Bio, Inc. raised USD 372. 25 mn in Series D funding, led by Andreessen Horowitz and supported by new investors including FPV Ventures and Sanofi. The funding will be utilized for drug pipeline growth and further development of their artificial intelligence-driven drug development platform.

The company is actively designing new products to enhance its platform capabilities, with plans to expand its services into additional markets across Europe and Asia by 2025.